BOS Basel 2026
Visit booth #1/2 at BOS Basel 2026 to discover how our integrated
CDMO and CRO capabilities can help streamline your drug development journey.
June 30–July 1, 2026 | Basel, Switzerland | Booth #1/2
About BOS Basel 2026
Biotech Outsourcing Strategies (BOS) Basel 2026 will bring together R&D outsourcing leaders from across the biopharma industry to share insights, strengthen partnerships, and build new business relationships.
Focused on development-stage CMC for small molecules, biologics, and novel therapeutic entities, the event features high-quality networking opportunities and a dynamic exhibition of CRO and CDMO capabilities.
Event details
Date: June 30–July 1, 2026
Location: Congress Center Basel
Booth Number: #1/2
Event Website: BOS Basel 2026
Why Thermo Fisher Scientific?
At BOS Basel 2026, connect with Thermo Fisher Scientific’s global team of drug development experts to explore how we simplify development-stage outsourcing.
Through Accelerator™ Drug Development, we integrate CDMO and CRO capabilities across CMC, clinical research, manufacturing, and supply—seamlessly supporting programs across therapeutic areas and modalities.
Our connected approach reduces complexity, improves continuity, and helps keep your program on track from preclinical development through commercialization.
Attend our session:
“Beyond Fill-Finish: How Integrated Sterile DP, Clinical Supply and CRO Execution Accelerates Biotech Programs”
- Date: Tuesday, June 30, 2026
- Time: 11:20–11:40 a.m. (20 minutes)
- Speaker: Dr. Alessandro Chreim, Global SME, Sterile Drug Products, Thermo Fisher Scientific
Sterile drug product development is more than fill-finish. Successful clinical execution requires alignment across formulation, analytics, GMP manufacturing, stability, labeling, packaging, clinical supply, and trial delivery.
This presentation uses sterile drug product development as the technical anchor to illustrate how fragmented outsourcing can create handoffs, knowledge gaps, and timeline risk, while an integrated CDMO/CRO/clinical supply model can improve execution through connected planning, coordinated governance, and earlier risk mitigation.
The session will also highlight how reducing complexity across the development pathway can help biotech sponsors progress more confidently from development to the clinic—and ultimately deliver therapies to patients in need.
Meet us at BOS Basel 2026
We look forward to seeing you in Basel. Pre-book a meeting with our team to start the conversation.
Stay connected to new discoveries, innovations, and expert scientific opinions.
Follow us on social media for the latest up-to-date event happenings.
We look forward to seeing you soon